ATNX News and Press, Athenex Inc. From 09/01/20

FDA grants Priority Review and sets PDUFA target action date of February 28, 2021 FDA indicated that it is not currently planning to hold an advisory committee meeting BUFFALO, N.Y., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company...

Athenex, Inc. (ATNX) Q2 2020 Earnings Conference Call August 06, 2020 08:00 A.M. ET Company Participants Michael Wood - LifeSci Advisors Johnson Y.N. Lau - Chairman & CEO Rudolf Kwan - Chief Medical Officer Timothy Cook - SVP of Global Oncology Jeffrey M. Yordon - COO and...

Image source: The Motley Fool. Athenex, Inc.   (NASDAQ: ATNX) Q2 2020 Earnings Call Aug 7, 2020 , 10:00 p.m. ET Operator Continue reading

Regulatory progress for Oral Paclitaxel and tirbanibulin ointment is on track Continued momentum in building commercialization infrastructure and supply chain for Oral Paclitaxel Announced two financing agreements for up to $275 million in aggregate Product sales guidance for 2020 ra...

BUFFALO, N.Y., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it has entered into a&#...

BUFFALO, N.Y., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of Robert J....

BUFFALO, N.Y., July 27, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will release second ...

July 21, 2020 FN Media Group Presents USA News Group News Commentary Vancouver, BC – July 21, 2020 – USA News Group   – Researchers at the University of Cincinnati Cancer Center have found a potential new combination therapy for breast cancer tha...

Athenex (NASDAQ: ATNX ) has entered into a $225M loan agreement with funds managed by Oaktree Capital Management, L.P. More news on: Athenex, Inc., Healthcare stocks news, , Read more ...

BUFFALO, N.Y., June 22, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and re...